Pharmacokinetics and pharmacogenetics of 13-cis-retinoic acid in the treatment of neuroblastoma

Therapie

Volumn 62, Issue 2, 2007, Pages 91-93

  Veal, Gareth ^a   Rowbotham, Sophie ^a   Boddy, Alan ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

13 cis retinoic acid; Neuroblastoma; Pharmacogenetics; Pharmacokinetics; Plasma concentration; Retinoid

Indexed keywords

4 OXOISOTRETINOIN; 6ALPHA HYDROXYPACLITAXEL; CYTOCHROME P450; CYTOCHROME P450 26A1; CYTOCHROME P450 2C8; DRUG METABOLITE; ISOTRETINOIN; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HYPERCALCEMIA; LIVER TOXICITY; LOW DRUG DOSE; NEUROBLASTOMA; PHARMACOGENETICS; PRIORITY JOURNAL; SKIN TOXICITY; ARTICLE; BLOOD; GENETICS; PROMYELOCYTIC LEUKEMIA;

ANTINEOPLASTIC AGENTS; HUMANS; ISOTRETINOIN; LEUKEMIA, PROMYELOCYTIC, ACUTE; NEUROBLASTOMA; PHARMACOGENETICS;

EID: 34548603362     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2007020     Document Type: Conference Paper

References (19)

1. Fenaux P, Chevret S, Guerci A, et al. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukaemia. European APL Group. Leukemia 2000; 14: 1371-7
2. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341: 1165-73
3. Adamson PC, Widemann BC, Reaman GH, et al. A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: a joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group study. Clin Cancer Res 2001; 7: 3034-9
4. Smith MA, Anderson B. Where to next with retinoids for cancer therapy? Clin Cancer Res 2001; 7: 2955-7
5. Finklestein JZ, Krailo MD, Lenarsky C, et al. 13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the Childrens Cancer Study Group. Med Pediatr Oncol 1992; 20: 307-11
6. Kohler JA, Imeson J, Ellershaw C, et al. A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy. Br J Cancer 2000; 83: 1124-27
7. Matthay KK, Reynolds CP. Is there a role for retinoids to treat minimal residual disease in neuroblastoma? Br J Cancer 2000; 83: 1121-3
8. Muindi J, Frankel SR, Miller WH, et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations - implications for relapse and retinoid resistance in patients with acute promyelocytic leukemia. Blood 1992; 79: 299-303
9. Villani MG, Appierto V, Cavadani E, et al. Identification of the fenretinide metabolite 4-oxo-fenretinide present in human plasma and formed in human ovarian carcinoma cells through induction of cytochrome P450 26A1. Clin Cancer Res 2004; 10: 6265-75
10. Veal GJ, Coulthard SA, Boddy AV. Chemotherapy individualization. Invest New Drugs 2003; 21: 149-56
11. Khan AA, Villablanca JG, Reynolds CP, et al. Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation. Cancer Chemother Pharmacol 1996; 39: 34-41
12. Veal GJ, Errington J, Koller KE, et al. Pharmacokinetics and metabolism of 13-cis-retinoic acid in children with neuroblastoma. Proc AACR 2003; 44: 3554
13. Marill J, Capron CC, Idres N, et al. Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids. Biochem Pharmacol 2002; 63: 933-43
14. Dai D, Zeldin DC, Blaisdell JA, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11: 597-607
15. Chen H, Fantel AG, Juchau MR. Catalysis of the 4-hydroxylation of retinoic acids by cyp3a7 in human fetal hepatic tissues. Drug Metab Dispos 2000; 28: 1051-7
16. Ray WJ, Bain G,Yao M, et al. CYP26, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family. J Biol Chem 1997; 272: 18702-8
17. Sonneveld E, van den Brink CE, van der Leede BM, et al. Human retinoic acid (RA) 4-hydroxylase (CYP26) is highly specific for all-trans-RA and can be induced through RA receptors in human breast and colon carcinoma cells. Cell Growth Differ 1998; 9: 629-37
18. Fisher MB, Paine MF, Strelevitz TJ, et al. The role of hepatic and extrahepatic UDP-glucuronyltransferases in human drug metabolism. Drug Metab Rev 2001; 33: 273-97
19. Bhasker CR, McKinnon W, Stone A, et al. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 2000; 10: 679-85